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doi:10.1016/j.asjsur.2012.04.017Summary Background/Objective: Hepatocyte transplantation is a promising alternative to
liver transplantation in children with liver metabolic disorders and acute liver failure.
Currently, it is difficult to assess rapidly hepatocyte function before transplantation. The
aim of this study was to investigate whether the uptake and release of indocyanine green
(ICG) by hepatocytes could be used.
Methods: Human hepatocytes (106 cells) isolated from unused donor livers were incubated
at 37C for 30 minutes with ICG (0e2 mg/mL) in both cell suspension and on collagen-coated
culture plates. Cells were then incubated in medium without ICG for 3 hours with superna-
tants collected at 1, 2 and 3 hours for measurement of ICG release. Cell viability was deter-
mined by trypan blue exclusion, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay (mitochondrial dehydrogenase activity) and sulforhodamine B (SRB)
assay (cell attachment). HepG2 cells were also used.
Results: ICG was taken up and secreted by hepatocytes with the release reaching a plateau
level soon after 1 hour. Concentrations of ICG > 1.0 mg/mL had toxic effects on hepato-
cytes. Hepatocytes incubated with 1.0 mg/mL ICG had higher mitochondrial dehydrogenase
activity compared to 0.5 mg/mL ICG or control cells (0.025  0.0004 OD unit vs.
0.019 0.0008 OD unit or 0.020 0.002 OD unit, p< 0.05). Incubation of HepG2 cells with
ICG reduced albumin production (98.9 0.02 ng/mL, 66.6  0.05 ng/mL and 39.1 0.4 ng/
mL for control cells, and 0.5 mg/mL and 1.0 mg/mL ICG, respectively), and decreased
[3H]-thymidine incorporation in a dose-dependent manner. Addition of taurine (20 mM) to
plated hepatocytes gave greater release of ICG and hepatocyte attachment compared to
controls, at all ICG concentrations (SRB 1.360  0.083 optical density units vs.
0.908 0.159 optical density units, pZ 0.011 at 1.0 mg/mL).Liver Studies, King’s College London, King’s College Hospital, Denmark Hill, London SE5 9RS, UK.
c.uk (R.R. Mitry).
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10 C.-M. Ho et al.Conclusion: With further refinement, ICG could be used to develop a rapid assay for assess-
ment of the function of isolated human hepatocytes.
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reserved.1. Introduction
Hepatocyte transplantation was first introduced into
clinical practice in 19921 as a promising alternative to
liver transplantation or as a bridging therapy for patients
with metabolic diseases and acute liver failure.2,3 Hepa-
tocyte transplantation is a safe and less-invasive proce-
dure for patients with liver disease than whole organ
transplantation. Animal studies have clearly proven the
efficacy of hepatocyte transplantation, however, this has
not translated into clinical practice where there is often
limited benefit.4 One of the major reasons for this is the
quality of the hepatocytes that have been infused, which
are often isolated from livers that have been rejected for
transplantation. Currently, trypan blue exclusion is used
as a rapid test of cell viability, which determines cell
integrity by staining the nuclei of dead cells. This test
does not reflect the metabolic function of the hepato-
cytes, which is important in vivo. Measures of specific
synthetic function such as albumin and clotting factor 7
synthesis require cell culture, and are not applicable to
determine suitability of hepatocytes for immediate infu-
sion into a patient.
Current commercial assays use technologies that are
either nonspecific to hepatocytes (ATP detection; redox
activity, membrane integrity) or not available for routine
clinical use (P450 assays by HPLC, mass spectrometry).
Indocyanine green (ICG) is an organic anion used in hep-
atobiliary surgery to assess liver reserve before resection,
and is specifically eliminated by the liver.5 ICG uptake by
hepatocytes assessed by microscopy has been recently used
to assess the in vitro function of stem-cell-derived hepa-
tocytes.6,7 At the cellular level, ICG is taken up by hepa-
tocytes via the transporter organic anion transport protein
(OATP)1B1 [OATP2 (rats)/OATP-C (humans)], which is
exclusively expressed in the basolateral membrane of
hepatocytes,8e10 as used by bilirubin,11 and then excreted
into the bile canaliculi by multidrug resistance protein 2,
which requires ATP.12,13 ICG uptake can also reflect the
degree of hepatic triglyceride content in a doseeresponse
relationship.14
In this study we investigated whether quantitative
measurement of the uptake and release of ICG by human
hepatocytes has potential to develop a rapid test of
metabolic function before hepatocyte transplantation.
2. Materials and methods
2.1. Isolation and culture of human hepatocytes
Hepatocytes were isolated from unused donor liver tissue
using a modified collagenase perfusion technique.15 Donor
data and liver characteristics are shown in Table 1. Viabilitywas assessed by 0.4% trypan blue exclusion test. Cell
suspensions contained 106 cells. Collagen-coated culture
plates were seeded with fresh or defrosted cells, which
were then incubated in Williams’ medium E, supplemented
as previously described.16 HepG2 cells (human hepatocel-
lular carcinoma cell line) were cultured in RPMI1640/10%
fetal calf serum overnight before use. Cell suspensions
were used for experiments with ICG immediately. Cells
were cultured overnight to determine the effects of ICG
treatment on hepatocyte functions.
2.2. ICG treatment
ICG dry powder 5 mg (Cardiogreen; SigmaeAldrich, Gil-
lingham, Dorset, UK) was dissolved in 1 mL solvent [100 mL
dimethyl sulfoxide (DMSO), CryoSure-DMSO; WAK-Chemie
Medical GmbH, Steinbach, Germany] and culture medium
was added to obtain a stock of 5 mg/mL. The solution was
shaken for 2 minutes to ensure that the powder was
completely dissolved. The experimental solutions used
were different concentrations of ICG (0.25 mg/mL, 0.5 mg/
mL, 1.0 mg/mL and 2.0 mg/mL) and in further experiments
at 0.5 mg/mL and 1.0 mg/mL. Cells were incubated with
ICG as a suspension or plated for 30 minutes at 37C in 95%
O2/5% CO2. Cells were washed with phosphate-buffered
saline (PBS) and centrifuged to obtain the pellets if in
suspension and then reincubated in medium alone to
determine ICG release. Supernatants were collected after 1
hour, 2 hours and 3 hours for measurement of ICG
concentration against a standard curve using a DYNEX
Technologies MRX microplate reader, (supplied by Prior
Laboratory Supplies Ltd., Forest Row, East Sussex, UK), at
optical density 820 nm (OD820). Plates were reincubated
overnight, and cell function analyzed using the following
assays.
2.3. Cell attachment: sulforhodamine (SRB) assay
To determine cell numbers on culture plates, the SRB
assay was performed as described previously.17 In each
well of the 96-well plate, 50 mL ice-cold 50% trichloro-
acetic acid solution was gently layered on top of the
medium overlaying the cells. The plates were then incu-
bated for 1 hour at 4C. Wells were rinsed five times with
water and the cells stained with 0.4% SRB solution (100 mL
stain/well) for 15 minutes at room temperature. SRB
staining solution was poured off, wells were rinsed five
times with 1% acetic acid to remove unbound dye, and left
to air dry. The bound SRB dye was then solubilized by
adding unbuffered Tris-base solution (200 mL/well), and
plates were placed on a plate shaker for 1 hour at room
temperature. Plates were then read at OD564, using
a microplate reader.
Table 1 Details of donor livers used for experiments.
Liver Age (yr) Sex Cause of death Status at retrieval Cold ischemia (h) Warm ischemia (min) Viability (%)
1 31 F ICH Cadaveric 10 d 70.0
2 57 M ICH NHBD fatty liver 12 15 79.8
3 52 M ICH NHBD 13 20 52.1
4 26 M Cardiac arrest NHBD 12.5 22 76.0
5 76 M ICH Cadaveric 10 d 78.6
6 60 F Heart attack NHBD 12 19 39.7
7 28 M Cardiac arrest Cadaveric 11.5 d 67.0
FZ female; ICHZ intracranial hemorrhage; MZmale; NHBDZ non-heart-beating donor.
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dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT) assay
The assay was as described previously.18 Briefly, 20 mL MTT
solution was added to 200 mL medium in each well of the
96-well plate, and the plate incubated at 37C for 4 hours.
The medium was then removed by aspiration, 120 mLFigure 1 Characteristics of ICG uptake and release by human he
ICG: after ICG incubation (A1 and A3) and 3 hours release of ICG (A
cells. (B) ICG release into the supernatant by human hepatocytes in
cells in plates release ICG with time as shown as decrease in the pe
hepatocytes from different donors. ICGZ indocyanine green.isopropanol/HCl added per well, the plate shaken for 15
minutes, and absorbance at OD630 measured.
2.5. [3H]-thymidine incorporation into HepG2 cells
The effect of the ICG (0 mg/mL, 0.5 mg/mL and 1 mg/mL)
on DNA synthesis of HepG2 cells was assessed using [3H]-
thymidine incorporation assay. The medium in each wellpatocytes and HepG2 cells in vitro. (A) Uptake and release of
2 and A4). A1 and A2: human hepatocytes; A3 and A4: HepG2
creased with ICG concentration used for incubation. (C) HepG2
rcentage of green cells. (D) Release patterns of ICG by human
12 C.-M. Ho et al.was replaced with an equal volume (200 mL) of fresh
medium containing [3H]-thymidine (0.5 mCi/well, Amer-
sham International, Amersham, Bucks, UK). The plates
were incubated overnight. The cells were then harvested
onto glass fiber membranes using a cell harvester (Filter-
Mate; Packard Instruments, Pangbourne, Berks, UK). The
filters were dried and the radioactivity counted (MATRIX
9600 Plate Counter; Packard Instruments) to determine the
incorporation of radioactivity into the cells.
2.6. Albumin synthesis
Concentration of albumin in culture media was determined
by enzyme-linked immunosorbent assay (ELISA) kit (Bethyl
Laboratories, Montgomery, TX, USA) using a sheep anti-
human albumin antibody. The assay was done according to
the manufacturer’s instructions. The absorbance was read
at 450 nm.
2.7. Cell viability: staining with fluorescein
diacetate (FDA)/ethidium bromide (EtBr)
A stock solution of FDA (SigmaeAldrich) was prepared by
dissolving 5 mg/mL in DMSO. The FDA working solution was
freshly prepared by adding 0.01 mL stock to 5 mL EtBr
(SigmaeAldrich) stock solution prepared by dissolving
10 mg/mL in PBS. Cells in supernatants were collected by
washing with 0.5 mL PBS at room temperature and centri-
fugation for 50 g at 4C for 4 minutes. Cells were resus-
pended with 0.2 mL FDA/EtBr solution and incubated for 6
minutes at room temperature. Cells were then collected
again by removing the staining solution, washing twice with
PBS, and centrifugation. Stained cells were resuspended
with two drops of antifading reagent and placed ontoFigure 2 Functional disturbances of human hepatocytes and He
showed increased mitochondrial function in hepatocytes (top)
(B) Albumin synthesized by HepG2 cells decreased in a dose-res
(nZ 2). (C) Incubation with 1.0 mg/mL ICG decreased HepG2
MTTZ (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromia microscope slide with a coverslip. The cells were
observed under a fluorescent microscope (filter set 09
ZEISS, excitationZ 450e490 nm, emissionZ 520 nm),
whereas nuclei were stained red (excitationZ 506 nm,
emissionZ 610 nm) at 100e400 magnification.
2.8. Taurine treatment of hepatocytes
Fresh human hepatocytes were cultured overnight with
taurine (SigmaeAldrich) at 20 mM, and cells were incu-
bated with ICG and tested as above.
2.9. Statistical analysis
Statistical analysis of the results was carried out using
Student’s t test and Pearson correlation test. A value of
p< 0.05 was considered significant.
3. Results
3.1. ICG uptake and release by hepatocytes and
HepG2 cells
Human hepatocytes and HepG2 cells took up ICG with cells
turning green after incubation for 30 minutes. After 3 hours,
the ICGwas released by the cells (Fig. 1A). The release of ICG
by human hepatocytes (Fig. 1B) andHepG2 cells (Fig. 1C)was
related to the initial ICG concentration during uptake from
both the loss of green color of the cells and appearanceof ICG
detected microscopically in the culture medium. There was
a significant correlation between the ICG release and the
viability of human hepatocytes measured by trypan blue
uptake (rZ 0.85, pZ 0.008). The pattern of ICG release inpG2 cells following ICG treatment. (*p< 0.05). (A) MTT assay
and HepG2 cells (bottom) incubated with 1.0 mg/mL ICG.
ponse relationship as increased ICG incubation concentration
cell proliferative activity (nZ 2). ICGZ indocyanine green;
de.
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a plateau level soon after 1 hour (Fig. 1D). This effect was
seen with cells both in suspension and in culture, but tended
to be more rapid in culture.3.2. Effect of incubation with ICG on hepatocyte
function
The effects of increasing concentrations of ICG on hepa-
tocyte function were determined. With the MTT assay,Figure 3 Human hepatocytes and HepG2 cells detach when rel
HepG2 cells (bottom) on incubation with increasing ICG concent
ethidium bromide showed that more viable cells detached when in
green.hepatocytes incubated with 1.0 mg/mL ICG had higher
mitochondrial dehydrogenase activity compared to 0.5 mg/
mL ICG or controls (0.025 0.0004 OD unit vs.
0.019 0.0008 or 0.020 0.002, p< 0.05 for hepatocytes;
0.038 0.004 vs. 0.025 0.003 or 0.025 0.004, p< 0.05
for HepG2 cells) (Fig. 2A).
Incubation of HepG2 cells with ICG reduced albumin
production (98.9 0.02 ng/mL, 66.6 0.05 ng/mL and
39.1 0.4 ng/mL for controls and 0.5 mg/mL and 1.0 mg/
mL ICG, respectively) and decreased [3H]-thymidine incor-
poration in a dose-dependent manner (Fig. 2B and 2C).easing ICG. (A) Detachment of human hepatocytes (top) and
ration. (B) Cell viability staining with fluorescein diacetate/
cubated with higher concentrations of ICG. ICGZ indocyanine
Figure 4 Effect of pretreatment with taurine on human
hepatocytes (*p< 0.05). (A) Human hepatocytes released more
ICG when pretreated with taurine. When incubated with
1.0 mg/mL ICG, the pattern of ICG release was maintained in
taurine-pretreated hepatocytes. (B) Pretreatment with taurine
increased hepatocyte attachment. Following incubation with
ICG for 30 minutes, plates were reincubated overnight to study
cell attachment. Cells pretreated with taurine were attached
better with 1.0 mg/mL ICG. (C) Taurine-pretreated hepato-
cytes had lower MTT activity on incubation with 1.0 mg/mL
than with 0.5 mg/mL ICG. ICGZ indocyanine green; MTTZ (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
14 C.-M. Ho et al.Cells had lower attachment when tested 6 hours after
incubation with increasing concentrations of ICG (Fig. 3A).
However, if the plates were reincubated overnight, the
cells reattached. To investigate these further, cells in the
supernatants were collected after incubation with ICG
(0e2 mg/mL) and stained with FDA/EtBr. Greater numbers
of viable cells were detached at higher ICG concentrations
(0.5 mg/mL and 1 mg/mL) than at 0.25 mg/mL ICG and in
the controls (Fig. 3B).
3.3. Effect of taurine on hepatocyte transport of
ICG
Pretreatment of fresh human hepatocytes with taurine in
culture overnight gave greater amounts of ICG release and
the pattern of ICG release was maintained with high ICG
concentrations (Fig. 4A). Compared with controls, taurine
also resulted in a higher degree of cell attachment, and
enhanced reattachment overnight following ICG incubation
(Fig. 4B). Pretreatment with taurine prevented the stimu-
latory effect on the MTT assay at 1.0 mg/mL ICG, but not at
0.5 mg/mL (Fig. 4C).
4. Discussion
The results of these experiments show that there is
a distinct pattern of uptake and release of ICG by human
hepatocytes that can be quantitated using readily available
laboratory equipment. Hepatocytes take up ICG in 30
minutes and then excrete the unchanged dye in 1e2 hours.
The specific uptake of ICG by intact hepatocytes is followed
by excretion via the ATP-dependant multidrug resistance
protein 2 transporter, which is the rate-limiting step,12 thus
being a dual measure of cell metabolic function. Cells with
impaired function will have reduced amounts of ATP which
will limit ICG excretion. There was a characteristic ICG
release curve for hepatocytes that showed a peak in the
second hour of incubation. In this preliminary study, only
a relatively small number of cell batches were used.
Further experiments are needed to define the ICG pattern
for cells isolated from fatty livers, which are likely to have
impaired function19 and those from non-heart-beating
donors exposed to warm ischemia.20
There was a correlation of ICG excretion with cell
viability by trypan blue exclusion, suggesting that trypan
blue exclusion is related to cell function in the range of cell
viabilities studied. However, ICG is specific to hepatocytes
and should reveal more about cellular function than just
membrane integrity. Ideally, any measure of hepatocyte
function should be correlated to engraftment and function
of hepatocytes after transplantation.
HepG2 cells, although they are transformed cells, had
a similar release pattern of ICG to normal hepatocytes.
They are thus a useful tool for developing the conditions for
an ICG test, having high viability as “best quality” hepa-
tocytes are not often available. However, HepG2 cells may
not predict metabolism in adult human liver cells, because
their expression of drug-metabolizing enzymes is
different.21 Incubation of human hepatocytes and HepG2
cells at concentrations > 0.5 mg/mL had effects on
cell metabolism including stimulation of mitochondrialdehydrogenase activity and inhibition of albumin synthesis
and proliferation of HepG2 cells. Other studies in retinal
cells have shown high concentrations of ICG to be toxic with
a proapoptotic effect.22 The concentration used to test
hepatocytes in vitro should be 0.5 mg/mL to avoid these
effects.
In the cell attachment experiments using the SRB assay,
we found that cells incubated with ICG had lower attach-
ment during ICG release but recovered to give better
attachment the next day. It is interesting to speculate
whether this is in someway related to location of the ICG
uptake OATP transporter on the basolateral membrane,
Functional assessment of human hepatocytes for cell transplantation 15which attaches to the collagen coating on the culture
plates.23 Whereas, the excretion of ICG is via the trans-
porter in the canalicular membrane of the hepatocyte.
Taurine has been shown to be involved in membrane
stabilization19 and can act as an antioxidant,24 and it was
used to modulate cell function to see the effects on ICG
transport. Hepatocytes pretreated with taurine appeared to
better tolerate better higher concentrations (1.0 mg/mL) of
ICG with increased cell attachment. Thus ICG disposition
could detect a protective effect on cell function.
In a recent study, Donato et al25 rapidly assessed the
cellular P450 enzyme function of human hepatocytes within
1 hour by HPLCetandem mass spectrometry. However,
these assays require sophisticated equipment and are not
available in everyday clinical use. They also determined
urea synthesis, which is a good specific marker of hepato-
cyte metabolic function, although this did not correlate
with cell viability. It is likely that a panel of rapid assays will
give the most useful data.
In conclusion, in vitro hepatocyte function can be
assessed by the ICG release pattern within 2 hours. Further
refinement of this assay, particularly in reducing the time
taken, should lead to a test of hepatocyte function to help
assess the quality of isolated human hepatocytes for
transplantation.
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